OliX Pharmaceuticals, Inc (KOSDAQ:226950)

South Korea flag South Korea · Delayed Price · Currency is KRW
42,000
+3,750 (9.80%)
Jul 18, 2025, 3:30 PM KST
286.74%
Market Cap831.57B
Revenue (ttm)5.89B
Net Income (ttm)-45.52B
Shares Out19.80M
EPS (ttm)-2,613.93
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,290,962
Average Volume405,177
Open39,700
Previous Close38,250
Day's Range39,150 - 42,500
52-Week Range10,490 - 64,000
Beta0.58
RSI54.18
Earnings DateAug 14, 2025

About OliX Pharmaceuticals

OliX Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company’s products pipeline includes OLX101A for skin scar; OLX104C for androgenic alopecia; OLX301A for age-related macular degeneration; OLX702A for metabolic dysfunction-associated steatohepatitis; OLX703A for hepatitis; and OLX301D for subretinal fibrosis. The company has a license and collaboration agreement with Hansoh Pharmaceuticals; development collaboration ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 66
Stock Exchange KOSDAQ
Ticker Symbol 226950
Full Company Profile

Financial Performance

In 2024, OliX Pharmaceuticals's revenue was 5.68 billion, a decrease of -66.73% compared to the previous year's 17.06 billion. Losses were -40.66 billion, 112.9% more than in 2023.

Financial Statements

News

There is no news available yet.